title: The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.
abstract: BACKGROUND
  One of the putative mechanisms of tumor immune escape is based on the hypothesis that carcinomas actively create an immunosuppressed state via the expression of indoleamine 2,3-dioxygenase (IDO), both in the cancer cells and in the immune cells among the tumor-draining lymph nodes (TDLN). In an attempt to verify this hypothesis, the patterns of expression of IDO in the cancer cells and the immune cells among colon cancers were examined.
  
  
  METHODS
  Seventy-one cases of pathologically-confirmed colon cancer tissues matched with adjacent non-cancerous tissues, lymph node metastases, and TDLN without metastases were collected at the Sun Yat-sen Cancer Center between January 2000 and December 2000. The expression of IDO and Bin1, an IDO regulator, was determined with an immunohistochemical assay. The association between IDO or Bin1 expression and TNM stages and the 5-year survival rate in colon cancer patients was analyzed.
  
  
  RESULTS
  IDO and Bin1 were detected in the cytoplasm of cancer cells and normal epithelium. In primary colon cancer, the strong expression of IDO existed in 9/71 cases (12.7%), while the strong expression of Bin1 existed in 33/71 cases (46.5%). However, similar staining of IDO and Bin1 existed in the adjacent non-cancerous tissues. Among the 41 cases with primary colon tumor and lymph node metastases, decreased expression of IDO was documented in the lymph node metastases. Furthermore, among the TDLN without metastases, a higher density of IDO+cells was documented in 21/60 cases (35%). Both univariate and multivariate analyses revealed that the density of IDO+cells in TDLN was an independent prognostic factor. The patients with a higher density of IDO+cells in TDLN had a lower 5-year survival rate (37.5%) than the cells with a lower density (73.1%).
  
  
  CONCLUSIONS
  This study demonstrated paradoxical patterns of expression of IDO in colon cancer. The high density IDO+cells existed in TDLN and IDO was down-regulated in lymph nodes with metastases, implying that IDO in tumor and immune cells functions differently.
authors.affiliation: State Key Laboratory of Oncology in South China, 651 Dongfeng R E, 510060, Guangzhou, PR China. gyf814@tom.com
authors.forename: Yan-Fang
authors.initials: YF
authors.lastname: Gao
authors.forename: Rui-Qing
authors.initials: RQ
authors.lastname: Peng
authors.forename: Jiang
authors.initials: J
authors.lastname: Li
authors.forename: Ya
authors.initials: Y
authors.lastname: Ding
authors.forename: Xing
authors.initials: X
authors.lastname: Zhang
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Wu
authors.forename: Zhi-Zhong
authors.initials: ZZ
authors.lastname: Pan
authors.forename: De-Sen
authors.initials: DS
authors.lastname: Wan
authors.forename: Yi-Xin
authors.initials: YX
authors.lastname: Zeng
authors.forename: Xiao-Shi
authors.initials: XS
authors.lastname: Zhang
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism; D003110:Colonic Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000235:genetics / Q000378:metabolism*; D008198:Lymph Nodes / Q000166:cytology / Q000201:enzymology / Q000276:immunology / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism; D015996:Survival Rate; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism
chemical_list: D048868:Adaptor Proteins, Signal Transducing; C101410:BIN1 protein, human; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D009687:Nuclear Proteins; D025521:Tumor Suppressor Proteins
references.citation: Clin Cancer Res. 2008 Nov 15;14(22):7251-9
references.pmid: 19010841
references.citation: Oncogene. 2008 Jun 26;27(28):3889-900
references.pmid: 18317452
references.citation: Cancer Biol Ther. 2007 Aug;6(8):1258-62
references.pmid: 17700060
references.citation: Cancer Immunol Immunother. 2009 Sep;58(9):1363-73
references.pmid: 19172271
references.citation: J Transl Med. 2008 Apr 22;6:19
references.pmid: 18430198
references.citation: Clin Cancer Res. 2008 Feb 1;14(3):654-9
references.pmid: 18245524
references.citation: J Am Coll Surg. 2008 May;206(5):849-54; discussion 854-6
references.pmid: 18471709
references.citation: Curr Opin Immunol. 2006 Apr;18(2):220-5
references.pmid: 16460921
references.citation: J Clin Invest. 2004 Jul;114(2):270-9
references.pmid: 15254594
references.citation: Immunol Rev. 2006 Oct;213:131-45
references.pmid: 16972901
references.citation: Trends Immunol. 2006 Feb;27(2):68-73
references.pmid: 16406698
references.citation: J Clin Invest. 2007 May;117(5):1147-54
references.pmid: 17476344
references.citation: Immunol Rev. 2006 Oct;213:146-58
references.pmid: 16972902
references.citation: J Transl Med. 2008 Oct 30;6:63
references.pmid: 18973649
references.citation: Int J Cancer. 1995 Jan 3;60(1):115-22
references.pmid: 7814143
references.citation: Diabetes. 2002 Feb;51(2):356-65
references.pmid: 11812742
references.citation: Nat Med. 2005 Mar;11(3):312-9
references.pmid: 15711557
references.citation: J Immunol. 2006 Oct 15;177(8):5639-46
references.pmid: 17015752
references.citation: Clin Cancer Res. 2009 Jan 15;15(2):641-9
references.pmid: 19147770
references.citation: J Transl Med. 2005 Apr 29;3(1):18
references.pmid: 15862126
references.citation: J Transl Med. 2005 Jan 28;3(1):5
references.pmid: 15679891
references.citation: Mol Cancer Ther. 2008 Dec;7(12):3859-66
references.pmid: 19074858
references.citation: Oncol Rep. 2007 Jun;17(6):1333-9
references.pmid: 17487387
references.citation: J Neurosurg. 2009 Aug;111(2):230-7
references.pmid: 19199463
references.citation: J Clin Invest. 2007 Sep;117(9):2570-82
references.pmid: 17710230
references.citation: Immunol Lett. 2007 Aug 15;111(2):69-75
references.pmid: 17644189
references.citation: Blood. 2006 Jul 1;108(1):228-37
references.pmid: 16522817
references.citation: J Cancer Res Clin Oncol. 2008 Nov;134(11):1247-53
references.pmid: 18438685
references.citation: Handb Exp Pharmacol. 2009;(188):165-96
references.pmid: 19031026
references.citation: Clin Cancer Res. 2006 Feb 15;12(4):1144-51
references.pmid: 16489067
references.citation: Curr Drug Metab. 2007 Apr;8(3):209-16
references.pmid: 17430109
references.citation: J Cancer Res Clin Oncol. 2008 May;134(5):525-33
references.pmid: 17909857
references.citation: Curr Drug Metab. 2007 Apr;8(3):237-44
references.pmid: 17430112
references.citation: Br J Cancer. 2007 Jun 18;96(12):1879-87
references.pmid: 17565341
references.citation: J Transl Med. 2008 Jul 22;6:37
references.pmid: 18644158
references.citation: J Clin Invest. 2004 Jul;114(2):280-90
references.pmid: 15254595
references.citation: Lancet. 2000 Dec 9;356(9246):1981-2
references.pmid: 11130529
references.citation: Int J Biochem Cell Biol. 2007;39(12):2167-72
references.pmid: 17320464
references.citation: Adv Exp Med Biol. 2003;527:91-5
references.pmid: 15206720
references.citation: J Transl Med. 2007 Nov 29;5:62
references.pmid: 18047662
references.citation: J Cell Physiol. 2007 Oct;213(1):137-43
references.pmid: 17477384
references.citation: Langenbecks Arch Surg. 2008 Nov;393(6):995-1003
references.pmid: 18064486
references.citation: Nat Rev Cancer. 2009 Jun;9(6):445-52
references.pmid: 19461669
references.citation: Cancer Res. 2007 Jan 15;67(2):792-801
references.pmid: 17234791
references.citation: Nat Rev Immunol. 2006 Apr;6(4):295-307
references.pmid: 16557261
references.citation: Biochim Biophys Acta. 2004 Feb 10;1661(1):106-12
references.pmid: 14967480
references.citation: Nat Rev Immunol. 2004 Oct;4(10):762-74
references.pmid: 15459668
references.citation: Br J Cancer. 2006 Dec 4;95(11):1555-61
references.pmid: 17117179
references.citation: Biochem Biophys Res Commun. 2005 Dec 9;338(1):12-9
references.pmid: 16176799
references.citation: Science. 1998 Aug 21;281(5380):1191-3
references.pmid: 9712583
references.citation: J Immunol. 2008 Sep 1;181(5):3291-300
references.pmid: 18714001
references.citation: Exp Eye Res. 2007 Nov;85(5):617-25
references.pmid: 17870068
references.citation: J Transl Med. 2003 Sep 19;1(1):5
references.pmid: 14572312
references.citation: Clin Cancer Res. 2007 Dec 1;13(23):6993-7002
references.pmid: 18056175
references.citation: Nat Med. 2003 Oct;9(10):1269-74
references.pmid: 14502282
references.citation: Clin Cancer Res. 2008 Apr 15;14(8):2310-7
references.pmid: 18413819